Menu
← Oncology Approval Tracker
FDA DECISION ·
Zusduri
mitomycin intravesical solution · UroGen Pharma
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with recurrent low-grade, intermediate-risk non-muscle-invasive bladder cancer.
LAMPGEN ANALYSIS
Why it matters
A bladder-instilled gel-forming mitomycin option addresses recurrent intermediate-risk low-grade disease.
What research teams should watch
Build capacity for weekly catheter instillations and harmonize follow-up cystoscopy and cytology across sites.
PRIMARY RECORDS